Drug intelligence / Profile preview

ADC-042

Development stage: Preclinical
Lead developer: iProgen Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

ADC-042 is an antibody-drug conjugate (ADC) currently in preclinical development for the treatment of osteoporosis. It is being developed by iProgen Biotech in collaboration with the Korea Basic Science Institute (KBSI). The molecule utilizes iProgen's ADC platform, which involves a targeting antibody conjugated to a small-molecule payload. The program is designed to leverage the specificity of antibody-mediated delivery to modulate bone remodeling processes, aiming to provide a targeted therapeutic approach for bone loss. As of the current pipeline status, the specific biological target and the identity of the small-molecule payload have not been publicly disclosed.

Beyond the preview

Go deeper on ADC-042.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADC-042.

Explore the full profile